1-(3,4,5-三甲氧基苯基)-2-硫脲 | 59083-54-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硫脲
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3,4,5-三甲氧基苯基)-2-硫脲
• 英文名称: 1-(3,4,5-trimethoxyphenyl)thiourea
• 英文别名: 3,4,5-trimethoxyphenylthiourea；1-(3,4,5-Trimethoxyphenyl)-2-thiourea；(3,4,5-trimethoxyphenyl)thiourea
• CAS: 59083-54-4
• 化学式: C₁₀H₁₄N₂O₃S
• mdl: MFCD00060447
• 分子量: 242.299
• InChiKey: ZHVXETDHOROSGO-UHFFFAOYSA-N

物化性质

• 熔点：
  204-206°C

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  97.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  1-(3,4,5-三甲氧基苯基)-2-硫脲 在 三甲基铝 、 氯化铵 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 5-methyl-4-{2-[(3,4,5-trimethoxyphenyl)amino](1,3-thiazol-4-yl)}thiophene-2-carboxamidine
  参考文献：
  名称：

  Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

  摘要：

  The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00102-0
• 作为产物：
  描述：

  3,4,5-trimethoxyaniline hydrochloride 在 氨 、 碳酸氢钠 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 12.5h， 生成 1-(3,4,5-三甲氧基苯基)-2-硫脲
  参考文献：
  名称：

  Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

  摘要：

  The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00102-0

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Synthesis and bioevaluation of N,4-diaryl-1,3-thiazole-2-amines as tubulin inhibitors with potent antiproliferative activity
  作者：Maolin Sun、Qile Xu、Jingwen Xu、Yue Wu、Yueting Wang、Daiying Zuo、Qi Guan、Kai Bao、Jian Wang、Yingliang Wu、Weige Zhang

  DOI：10.1371/journal.pone.0174006

  日期：——

  inhibitors and evaluated for their antiproliferative activity in three human cancer cell lines. Most of the target compounds displayed moderate antiproliferative activity, and N-(2,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazol-2-amine (10s) was determined to be the most potent compound. Tubulin polymerization and immunostaining experiments revealed that 10s potently inhibited tubulin polymerization

  设计并合成了一系列含有三个带有氨基接头的芳香环的N，4-二芳基-1,3-噻唑-2-胺，作为微管蛋白抑制剂，并评估了它们在三种人类癌细胞系中的抗增殖活性。大多数目标化合物均显示出适度的抗增殖活性，N-（2,4-二甲氧基苯基）-4-（4-甲氧基苯基）-1,3-噻唑-2-胺（10s）被确定为最有效的化合物。微管蛋白聚合和免疫染色实验表明，10s以类似于CA-4的方式有效抑制微管蛋白聚合并破坏微管蛋白微管动力学。此外，10s以浓度和时间依赖性方式有效地诱导了SGC-7901细胞周期阻滞在G2 / M期。分子对接结果表明10s可以结合微管蛋白的秋水仙碱结合位点。
• Parallel Solution-Phase Synthesis of a 2-Aminothiazole Library Including Fully Automated Work-Up
  作者：Hans-Peter Buchstaller、Uwe Anlauf

  DOI：10.2174/138620711794474024

  日期：2011.2.1

  and effective procedure for the solution phase preparation of a 2-aminothiazole combinatorial library is described. Reaction, work-up and isolation of the title compounds as free bases was accomplished in a fully automated fashion using the Chemspeed ASW 2000 automated synthesizer. The compounds were obtained in good yields and excellent purities without any further purification procedure.

  描述了2-氨基噻唑组合文库溶液相制备的直接有效方法。使用Chemspeed ASW 2000自动合成仪以全自动方式完成标题化合物作为游离碱的反应，后处理和分离。无需任何进一步纯化步骤即可以良好的产率和优异的纯度获得化合物。
• Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors
  作者：Dominik Vogt、Julia Weber、Katja Ihlefeld、Astrid Brüggerhoff、Ewgenij Proschak、Holger Stark

  DOI：10.1016/j.bmc.2014.07.044

  日期：2014.10

  Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole

  鞘氨醇激酶（SphK1，SphK2）是鞘氨醇-1-磷酸酯（S1P）的主要调节剂，鞘氨醇-1-磷酸酯是一种参与多种生理和病理生理功能的多效脂质介体。SphK是新型抗癌和抗炎剂的靶标，这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病。本文中，我们描述了氨基噻唑类SphK抑制剂的设计，合成和评估。通过使用已知的SKI-II支架进行一系列修饰来定义结构-活性关系，已经发现了有效的抑制剂。我们确定了N-（4-甲基噻唑-2-基）-（2,4'-bithiazol）-2'-胺（24，ST-1803 ; IC 50 值：7.3μM（SphK1），6.5μM（SphK2））有望成为进一步体内研究和结构开发的有希望的候选者。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。